Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

Phase 1 Completed 38 enrolled Washington University School of Medicine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab

Non-randomizedCrossoverSingle-blindTreatment

Summary

An intestinal hormone called Glucose-dependent Insulinotropic Polypeptide (GIP) is released into the blood immediately after ingestion of a meal and plays an important role in regulating blood sugar levels. However, GIP is not active in persons with type 2 diabetes mellitus (T2DM) which is also known as adult onset or non-insulin-dependent diabetes. This study is being conducted to determine whether a hormone called xenin-25 can restore the activity of GIP in persons with T2DM.

Timeline

Start: 2009-10
Primary completion: 2014-02
Completion: 2014-02

Publications

Chowdhury S, Reeds DN, Crimmins DL, Patterson BW, Laciny E, Wang S, Tran HD, Griest TA, Rometo DA, Dunai J, Wallendorf MJ, Ladenson JH, Polonsky KS, Wice BM. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G301-9. doi: 10.1152/ajpgi.00383.2013. Epub 2013 Dec 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glucose-dependent Insulinotropic Polypeptide	Peptide	4 unknown	Intravenous
Subject	Xenin-25	Peptide	4 unknown	Intravenous

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

Summary

Timeline

Publications

Drugs

Indications